Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Robot arm aims to make kidney stone surgery safer and faster

NCT ID NCT07211555

Symptom relief Sponsor: AdventHealth Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new robotic system called LARC that helps surgeons precisely guide a needle into the kidney during surgery for large kidney stones. The goal is to make the procedure safer and faster by reducing the need for a separate pre-surgery step. Up to 45 adults will be enrolled, and researchers will track success rates, complications, and recovery for one month after surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
LARC Robotic System (Micromate™ Version 3.0)
What this could lead to
If this works, it could make kidney stone surgery safer, faster, and more effective by helping surgeons directly access the kidney without needing a separate procedure.
What could go wrong
This is a small early feasibility study with only 45 people, and the robotic system is not yet FDA-approved for this use. It may not work as well as hoped or could have unexpected complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 45 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2025

An estimate. Start dates often move.

Expected to finish

Jan 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Kidney stones larger than 2 cm * Staghorn renal calculi * Lower pole stones less than 2 cm * Anatomical abnormalities that reduce the likelihood of spontaneous stone fragment passage, such as: * Horseshoe kidney * Calyceal diverticulum * Ectopic or dystopic kidney * Stones that are refractory to prior treatment (e.g., ESWL or ureteroscopy) * Suspected malignant tumors or masses located in the planned renal access tract Exclusion Criteria: * Pregnancy * Active urinary tract infection (UTI) or untreated sepsis * Known bleeding disorders or uncorrectable coagulopathy despite medical management * Use of anticoagulant medications (e.g., warfarin, heparin, or DOACs) that cannot be safely discontinued * Allergy to contrast media that cannot be pre-medicated or managed * Severe cardiopulmonary comorbidities that contraindicate anesthesia or PCNL * Inability to provide informed consent * Participation in another investigational study that may interfere with study outcomes

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Kidney calculi are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Kidney Calculi kidney neoplasm nephrolithiasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Kidney calculi Kidney stones Refractory kidney stones Renal stone disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Advent Health Medical Group Urology at Celebration

    Celebration, Florida, 34747, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.